|
|
Article: Novartis, Antisoma Enter Deal: $100M Near-Term For AS1404.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
West Coast Editor
Roche's loss became Novartis' gain - maybe - in the increasingly competitive cancer space occupied by vascular disrupting agents (VDAs), where Antisoma plc holds a strong position.
Less than a year after losing partner F. Hoffman-La Roche Inc. for AS1404, Antisoma is getting $75 million up front in a licensing deal with Novartis AG and $25 million more when Phase III lung cancer trials with the VDA start early next year.
Antisoma's shares (LSE:ASM) rose [pounds sterling]4.75 (US$9.50) Thursday, or 9 percent, to close at [pounds sterling]57.25.
Longtime partner Roche, of Basel, Switzerland, declined to take AS1404 into ...